down arrow

Frontier Biotechnologies, Inc. (China)

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100005XF5
CNY
19.20
8.8 (84.62%)

Dec 05

SHG

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Frontier Biotechnologies, Inc. (China)
Why is Frontier Biotechnologies, Inc. (China) ?
1
Poor Management Efficiency with a low ROCE of 0%
  • The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of 21.43% and Operating profit at 1.09% over the last 5 years
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 104.11%, its profits have risen by 56.6%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Frontier Biotechnologies, Inc. (China) for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Frontier Biotechnologies, Inc. (China)
-100.0%
3.75
64.13%
China Shanghai Composite
15.19%
1.01
14.58%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
21.43%
EBIT Growth (5y)
1.09%
EBIT to Interest (avg)
-95.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.33
Sales to Capital Employed (avg)
0.07
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.93
EV to EBIT
-10.79
EV to EBITDA
-13.04
EV to Capital Employed
4.07
EV to Sales
20.01
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-37.75%
ROE (Latest)
-13.14%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY -161.68 MM

NET PROFIT(HY)

Higher at CNY -50.93 MM

ROCE(HY)

Highest at -15.92%

RAW MATERIAL COST(Y)

Fallen by -199.29% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 1.99%

-7What is not working for the Company
INTEREST(HY)

At CNY 4.72 MM has Grown at 8.63%

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.8%

Here's what is working for Frontier Biotechnologies, Inc. (China)
Operating Cash Flow
Highest at CNY -161.68 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Profit
Higher at CNY -50.93 MM
than preceding 12 month period ended Mar 2025
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (CNY MM)

Net Profit
At CNY -50.93 MM has Grown at 64.49%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is positive

Net Profit (CNY MM)

Inventory Turnover Ratio
Highest at 1.99%
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost
Fallen by -199.29% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Frontier Biotechnologies, Inc. (China)
Interest
At CNY 4.72 MM has Grown at 8.63%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debtors Turnover Ratio
Lowest at 0.8%
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."